Last reviewed · How we verify
N-acetylcysteine, intralipid, heparin
This is a combination therapy using N-acetylcysteine as an antioxidant, intralipid as a lipid emulsion for nutritional support, and heparin as an anticoagulant.
This is a combination therapy using N-acetylcysteine as an antioxidant, intralipid as a lipid emulsion for nutritional support, and heparin as an anticoagulant. Used for Supportive care in critical illness or acetaminophen overdose (N-acetylcysteine component), Parenteral nutrition support (intralipid component), Thrombosis prevention (heparin component).
At a glance
| Generic name | N-acetylcysteine, intralipid, heparin |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
N-acetylcysteine replenishes glutathione and reduces oxidative stress; intralipid provides essential fatty acids and calories for parenteral nutrition; heparin prevents thrombosis by inhibiting coagulation factors. This combination is typically used in critical care or specialized clinical settings to address multiple physiological needs simultaneously.
Approved indications
- Supportive care in critical illness or acetaminophen overdose (N-acetylcysteine component)
- Parenteral nutrition support (intralipid component)
- Thrombosis prevention (heparin component)
Common side effects
- Nausea and vomiting (N-acetylcysteine)
- Bleeding or hemorrhage (heparin)
- Lipemia or hypertriglyceridemia (intralipid)
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: